Published in J Cereb Blood Flow Metab on February 04, 2009
Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol (2011) 1.06
Energy failure: does it contribute to neurodegeneration? Ann Neurol (2013) 0.98
Clinical trials: past, current, and future for atypical Parkinsonian syndromes. Semin Neurol (2014) 0.83
Magnetic resonance imaging in progressive supranuclear palsy. J Neurol (2010) 0.83
Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study. BMC Med Genet (2012) 0.79
Mitochondrial complex 1 inhibition increases 4-repeat isoform tau by SRSF2 upregulation. PLoS One (2014) 0.77
Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord (2017) 0.77
Multireceptor fingerprints in progressive supranuclear palsy. Alzheimers Res Ther (2017) 0.75
Mitochondrial hyperpolarization in iPSC-derived neurons from patients of FTDP-17 with 10+16 MAPT mutation leads to oxidative stress and neurodegeneration. Redox Biol (2017) 0.75
NDUFA12L mitochondrial complex-I assembly factor: Implications for taupathies. Appl Transl Genom (2015) 0.75
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol (2009) 9.27
A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med (2006) 8.12
German Acupuncture Trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. Arch Intern Med (2007) 7.21
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol (2014) 6.28
Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet (2003) 3.51
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci (2004) 2.84
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
The REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. Mov Disord (2007) 2.64
Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet (2007) 2.17
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord (2003) 2.03
Hyperalgesia and functional sensory loss in restless legs syndrome. Pain (2013) 2.00
Cavernoma-related epilepsy: review and recommendations for management--report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (2013) 2.00
Standard requirements for GCP-compliant data management in multinational clinical trials. Trials (2011) 1.89
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst (2006) 1.86
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2008) 1.83
The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet (2003) 1.83
Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. PLoS Genet (2009) 1.81
The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.78
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Atlastin1 mutations are frequent in young-onset autosomal dominant spastic paraplegia. Arch Neurol (2004) 1.72
Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. Proc Natl Acad Sci U S A (2007) 1.71
Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci U S A (2007) 1.66
Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol (2011) 1.60
NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol (2008) 1.59
Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease. Exp Neurol (2005) 1.58
The German multicenter, randomized, partially blinded, prospective trial of acupuncture for chronic low-back pain: a preliminary report on the rationale and design of the trial. J Altern Complement Med (2003) 1.56
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord (2005) 1.54
Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres. Trials (2010) 1.53
GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology (2012) 1.51
Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes. Mov Disord (2012) 1.50
Hyperkalaemia in a tetraplegic adolescent due to de novo sodium channel mutation. Nephrol Dial Transplant (2007) 1.50
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord (2006) 1.49
Serum concentrations of s100b and NSE in migraine. Headache (2009) 1.48
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
How much phenotypic variation can be attributed to parkin genotype? Ann Neurol (2003) 1.44
Memory for public events in patients with unilateral temporal lobe epilepsy. Epilepsy Behav (2010) 1.41
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer (2010) 1.40
Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia. J Med Genet (2006) 1.37
Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain (2002) 1.37
Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A (2009) 1.35
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord (2008) 1.33
Extracorporeal shock wave therapy for plantar fasciitis: randomised controlled multicentre trial. BMJ (2003) 1.32
Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem (2003) 1.32
Dopamine and adult neurogenesis. J Neurochem (2006) 1.31
Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci (2003) 1.30
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol (2010) 1.28
Functional MRI using sensitivity-encoded echo planar imaging (SENSE-EPI). Neuroimage (2003) 1.28
The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem (2005) 1.27
Cytokines and epilepsy. Seizure (2011) 1.26
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer (2013) 1.26
Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat Neurosci (2011) 1.24
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain (2003) 1.24
Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol (2005) 1.23
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord (2014) 1.20
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol (2007) 1.20
Timecourse of health-related quality of life as determined 3, 6 and 12 months after stroke. Relationship to neurological deficit, disability and depression. J Neurol (2002) 1.20
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord (2010) 1.18
Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci (2007) 1.18
Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord (2008) 1.17
Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord (2010) 1.16
C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. J Alzheimers Dis (2013) 1.16
A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord (2014) 1.16
Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain (2009) 1.16
Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem (2003) 1.15
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord (2011) 1.15
Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord (2011) 1.14
Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord (2012) 1.14
Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics (2005) 1.13
PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins. J Cell Biol (2006) 1.12
Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed (2002) 1.12
Health-related quality of life in multiple system atrophy. Mov Disord (2006) 1.11
Rational therapeutic approaches to progressive supranuclear palsy. Brain (2010) 1.11
Processing stages underlying word recognition in the anteroventral temporal lobe. Neuroimage (2006) 1.10
Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels. J Neurosci (2004) 1.10
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer (2011) 1.09
Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord (2005) 1.09
Partial support for ZNF804A genotype-dependent alterations in prefrontal connectivity. Hum Brain Mapp (2011) 1.09
Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J Neurochem (2004) 1.08
Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol (2010) 1.08